Eli Lilly shares climbed approximately 39% in 2025, fueled by blockbuster demand for its dual‐agonist weight-loss drugs, Mounjaro for type 2 diabetes and Zepbound for obesity. Those therapies not only propelled revenue growth but also reinforced the company’s leadership in the obesity market, which analysts expect to approach $100 billion in annual sales by 2030. Executives credit the sustained uptake among both endocrinologists and primary‐care physicians for maintaining momentum, with millions of new prescriptions written over the past twelve months despite evolving payer coverage and patient access programs.

Building on its injectable success, Lilly is preparing to launch its first oral GLP-1 receptor agonist for weight management later this year. Company data show that patients switching from weekly injections to daily pills maintained the majority of their weight loss over a 12-week maintenance phase, highlighting both efficacy and patient convenience. In interviews at the JPMorgan Healthcare Conference, Lilly’s chief scientific officer emphasized that oral options will unlock new segments—such as needle-averse patients and those managed in primary care—potentially expanding the addressable population by tens of millions of adults. The pill’s development also aims to address real-world adherence challenges and may serve as a de-escalation therapy once injectable dosing requirements have tapered.

In a significant oncology milestone, the FDA awarded Breakthrough Therapy status to Lilly’s investigational agent sofetabart mipitecan for certain patients with platinum-resistant ovarian cancer. The designation follows early clinical data demonstrating durable tumor responses in heavily pretreated cohorts, with objective response rates exceeding those observed with existing salvage therapies. This regulatory recognition will fast-track interactions with the agency on pivotal trial design, potentially condensing review timelines and reinforcing Lilly’s commitment to advancing targeted treatments across multiple therapeutic areas.